A 2025 JAMA Network Open study analyzing two years of paid search results found that 11% of the search keywords or phrases paid for by Novo Nordisk contained the word "weight", even though the drug Ozempic is approved for type 2 diabetes and not for weight loss.
November 04, 2025
high
statistical
Analysis of paid search (sponsored) results purchased by a pharmaceutical manufacturer.
Wegovy and Ozempic are weight-loss drugs marketed by Novo Nordisk that belong to the GLP-1 class of medications.
high
definition
Identifies the therapeutic use, manufacturer, and pharmacological class of the drugs mentioned in the article.